ImmunoMolecular Therapeutics, Inc.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)β’ Click on a phase to view related trials
Phase 1
1 (100.0%)Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes
Phase 1
Completed
- Conditions
- Type1 Diabetes
- Interventions
- Drug: 1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsuleDrug: 350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsuleDrug: 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsuleDrug: 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Immunomolecular Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04625595
- Locations
- πΊπΈ
Prosciento, Inc., Chula Vista, California, United States
πΊπΈBarbara Davis Center, Aurora, Colorado, United States
πΊπΈRainier Clinical Research Center, Renton, Washington, United States
News
No news found